Paragon Sports Medicine

Home/ Peptides/ Humanin

BAck to all peptides

Humanin

Humanin is a naturally occurring 24-amino acid mitochondrial-derived peptide (MDP) first identified in the brains of Alzheimer's disease patients as a survival factor against amyloid-beta toxicity. Originally discovered as a neuroprotective agent, humanin represents a groundbreaking discovery in longevity medicine and cellular protection, emerging as a master regulator of cellular health, mitochondrial function, and aging processes.

This peptide has gained considerable attention in longevity medicine for its studied role in protecting against neurodegeneration, enhancing metabolic health, reducing systemic inflammation, and promoting healthy aging. Humanin exhibits unique properties as the first identified mitochondrial-derived peptide with systemic biological activity and maintains bioactivity across various physiological conditions, making it distinctive among therapeutic peptides with applications in age-related diseases and longevity optimization.

Chemical structure diagram of a complex polypeptide chain depicting a sequence of amino acids with peptide bonds and side chains.

Overview

Humanin is unique among therapeutic peptides as it is encoded by mitochondrial DNA (16S rRNA gene) and represents the first identified mitochondrial-derived peptide with systemic biological activity. The peptide is metabolized through standard peptide degradation pathways with excellent tissue distribution, and demonstrates detectability up to 12 hours post-administration using specialized analytical methods.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Chemical structure & Properties

  • Molecular Formula: C119H204N34O32S2.
  • Molecular Weight: 2,687 Da
  • Sequence: 24 amino acids (MAPRGFSCLLLLTSEIDLPVKRRA)
  • Half-life: 2-4 hours following subcutaneous administration
  • Stability: Stable peptide requiring refrigerated storage when reconstituted

Mechanism of Action

Humanin exerts its therapeutic effects through multiple interconnected molecular pathways:

Mitochondrial Function Enhancement

Humanin activates mitochondrial optimization pathways, leading to:

  • Increased mitochondrial respiration rates and ATP production in preclinical models
  • Protection against mitochondrial dysfunction and oxidative stress
  • Enhancement of mitochondrial biogenesis and quality control mechanisms
  • Stabilization of mitochondrial membrane potential and electron transport chain function

Neuroprotection and Synaptic Preservation

The peptide promotes neuronal survival through:

  • Reduced neuronal cell death in neurodegenerative disease models
  • Reduced synaptic loss in hippocampal neurons
  • Increased pro-survival Akt signaling pathway activation
  • Protection against amyloid-beta toxicity and tau pathology

Metabolic Regulation

Humanin influences metabolic health by:

  • Enhanced glucose uptake and insulin sensitivity in preclinical models
  • Improvement of metabolic profiles and reduction of metabolic syndrome risk
  • Optimization of glucose metabolism and energy homeostasis
  • Protection against age-related metabolic dysfunction

Anti-inflammatory Effects

The peptide demonstrates anti-inflammatory properties through:

  • Reduced pro-inflammatory cytokines (IL-6, TNF-α) in preclinical models
  • Decreased systemic inflammatory markers in preclinical models
  • Modulation of microglial activation and neuroinflammation
  • Enhancement of anti-inflammatory pathway activation

Areas Investigated in

the Research Literature

Longevity Applications

Lifespan Extension: Preclinical studies demonstrate humanin's efficacy in promoting:

  • Increased median lifespan in animal models
  • Reduced age-related pathologies and disease burden in animal models
  • Improvement in healthspan and functional capacity throughout aging
  • Delayed onset of age-related cognitive and physical decline

Mechanism: Humanin promotes healthy aging through mitochondrial optimization, cellular protection, and activation of longevity pathways, addressing fundamental mechanisms of aging at the cellular level.

Healthspan Enhancement: Research indicates potential benefits in:

  • Maintained cognitive function and memory capacity
  • Preserved physical performance and mobility
  • Enhanced metabolic health and stress resilience
  • Reduced incidence of age-related diseases

Neurological Applications

Neurodegenerative Disease Protection: Humanin demonstrates protective effects against:

  • Alzheimer's disease with significant protection against amyloid-beta toxicity
  • Parkinson's disease through dopaminergic neuron protection
  • Other neurodegenerative conditions including ALS and Huntington's disease
  • Reduced cognitive deficits in preclinical models

Mechanism: Neuroprotection through mitochondrial stabilization, anti-inflammatory effects, activation of survival signaling, and reduction of oxidative stress in neural tissues.

Metabolic Applications

Metabolic Health Enhancement: Preclinical evidence supports potential benefits in:

  • Enhanced insulin sensitivity and glucose tolerance
  • Lower observed risk of metabolic syndrome in cohort data
  • Prevention of beta-cell dysfunction and insulin resistance
  • Protection against diabetic complications

Mechanism: Improved metabolic health through enhanced mitochondrial function, improved insulin signaling, and optimization of cellular energy metabolism.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Current Clinical Evidence

Safety Profile and Considerations

Preclinical Safety Data

Extensive studies across multiple species demonstrate:

  • No evidence of significant toxicity at therapeutic doses
  • Tolerability assessed in preclinical models only
  • Natural occurrence in human tissues supports safety profile
  • Minimal adverse effects across various administration routes

Potential Concerns

Cellular Survival Enhancement Risk:

  • Theoretical concern regarding cellular survival enhancement in malignancy
  • No direct evidence of cancer promotion in current studies
  • Caution advised in patients with active malignancy or cancer history

Drug Interactions:

  • Potential hypoglycemia due to enhanced insulin sensitivity
  • Limited data on interactions with other medications
  • Careful glucose monitoring required in diabetic patients

Contraindications

Humanin should be avoided in:

  • Active malignancy (theoretical concern regarding cellular survival enhancement)
  • Known hypersensitivity to humanin or related peptides
  • Severe hypoglycemia or unstable diabetes requiring frequent monitoring
  • Pregnancy and breastfeeding (insufficient safety data)

Regulatory Status and Legal Considerations

Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.

FDA Status

  • Classification: Research peptide, not approved for therapeutic use
  • Approval Status: Not approved for human therapeutic use
  • Development Stage: Preclinical development with limited human data
  • Regulatory Position: Early-phase human studies needed for regulatory advancement

WADA Status

  • Classification: Not specifically prohibited in current regulations
  • Athletic Use: Status unclear for competitive sports applications
  • Testing: Limited detection methods available for monitoring

Legal Availability

  • Commercial Status: Not FDA-approved for human therapeutic use.
  • Market Presence: Available through research-chemical suppliers and research institutions.
  • Quality Control: Products marketed for research are not regulated for clinical purity, potency, or sterility.
  • Clinical Use: Limited to research settings and experimental protocols
Man seated indoors with a soccer ball in natural light, representing Paragon’s musculoskeletal recovery expertise and regenerative treatment focus.

Conclusion

What the evidence supports

Humanin is a mitochondrial-derived peptide studied in cell-culture, animal models and human observational studies for associations with neuroprotection, metabolic health and aging. These findings are largely preclinical or correlational; there are no controlled human trials establishing efficacy, no standardized dosing and no long-term safety data. Humanin is not FDA approved and remains a research compound. This page summarizes the published research and nothing further.

HUMANIN SCIENTIFIC

DATA SUMMARY

MOLECULAR CHARACTERISTICS
PRECLINICAL EFFICACY DATA
CLINICAL EVIDENCE SUMMARY
SAFETY PROFILE
REGULATORY STATUS
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
2,687 Da
24 residues
2-4 hours (hepatic)
High via subcutaneous and IV routes
12 hours
Application
Lifespan Extension
Neuroprotection
Metabolic Health
Anti-inflammatory
Reported outcome (model)
Lifespan effects reported in animal models only
Reduced neuronal death
Enhanced insulin sensitivity
Reduced pro-inflammatory cytokines
Study Type
Aging Review
Lifespan Study
Neuronal Protection
Population
Systematic analysis (Coradduzza)
Animal models (Yen)
Hippocampal models (Zárate)
Results
Multifaceted protective effects
Lifespan extension reported in animal models
Reduced synaptic loss
Limitations
Limited human clinical data
Human trials needed
Clinical translation required
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
No significant toxicity in animal studies
Tolerability assessed in preclinical models only
No human adverse-event data published
No long-term human safety data available
Authority
FDA
WADA
DEA
Classification
Research Peptide
Not specifically prohibited
Unscheduled
Status
Not approved for human use
Status unclear
Not controlled substance

About this library

This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.

This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Humanin is not approved by the FDA for human therapeutic use. The peptide may affect glucose metabolism, requiring careful monitoring in diabetic patients. Patients should consult with qualified healthcare providers before considering any peptide therapy.

Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.

References

01
Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases. Life Sci. 2021.
02
Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders. Arch Cardiovasc Dis. 2020.
03
Humanin: A mitochondria-derived peptide with emerging properties. Ann Cardiol Angeiol. 2020.
04
Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases. Expert Opin Ther Targets. 2019.
05
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001.